2022
Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study
Kridin K, Valido K, Cohen J, Cohen A. Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study. Archives Of Dermatological Research 2022, 315: 429-435. PMID: 35871185, DOI: 10.1007/s00403-022-02369-5.Peer-Reviewed Original ResearchConceptsPeripheral vascular diseaseClalit Health ServicesCerebrovascular accidentHidradenitis suppurativaMyocardial infarctionHazard ratioVascular diseasePopulation-based retrospective cohort studyRisk of CVAIncidence of MIEthnicity-matched control subjectsMultivariate Cox regression analysisRisk of MIRetrospective cohort studyCox regression analysisOverall incidence ratePopulation-based studyCause mortalityCohort studyControl subjectsPrognostic outcomesEpidemiological findingsIncidence ratePatientsHealth services
2020
Early Adoption of Dupilumab in the Medicare Population in 2017.
Cheraghlou S, Cohen JM. Early Adoption of Dupilumab in the Medicare Population in 2017. The Yale Journal Of Biology And Medicine 2020, 93: 675-677. PMID: 33380928, PMCID: PMC7757055.Peer-Reviewed Original ResearchConceptsAtopic dermatitisRural-Urban Continuum CodesMedicare populationHealth Statistics Urban-Rural Classification SchemeInjectable biologicsSevere atopic dermatitisRetrospective cohort studyCohort studyPatient outcomesDupilumabFirst drugMedicare Provider UtilizationFDA approvalUtilization trendsFirst FDAFuture interventionsProvider UtilizationPotential targetBiologicsDisease treatmentPatientsTreatmentFirst yearMore rural regionsContinuum Codes